By bringing together clinical research with high performance protein analysis by proteomics technologies, this comprehensive handbook defines a new discipline in molecular medicine that will revolutionize treatment and prevention of cancer, stroke and other severe diseases. Unparalleled in its scope and depth, this book brings together proteomic approaches in diagnosis and treatment from all clinical fields, including clinical toxicology. The result is a new discipline in molecular medicine that will revolutionize the treatment and prevention of cancer, stroke and other severe…mehr
By bringing together clinical research with high performance protein analysis by proteomics technologies, this comprehensive handbook defines a new discipline in molecular medicine that will revolutionize treatment and prevention of cancer, stroke and other severe diseases.Unparalleled in its scope and depth, this book brings together proteomic approaches in diagnosis and treatment from all clinical fields, including clinical toxicology. The result is a new discipline in molecular medicine that will revolutionize the treatment and prevention of cancer, stroke and other severe diseases.Following an overview of clinical proteomics, the authors look at the technologies available, before moving on to cancer, cardiopulmonary disease, diabetes and stroke. A whole section is devoted to toxicity and the work is rounded off with a discussion of the future of clinical proteomics.
Jennifer Van Eyk is the Director of the Hopkins National Heart, Lung, and Blood Institute (NHLBI) Proteomics Center at Johns Hopkins University in Baltimore, Maryland. She was previously a group leader in the department of physiology at Queens University, Kingston (Canada) where she developed novel methods to investigate the reasons for heart failure and coronary artery disease. In 2000, she was awarded the Canadian Premier's Research Excellence Award.
Michael Dunn was recently appointed as Professor of Biomedical Proteomics at University College, Dublin (Ireland), where he is doing proteomics research in the areas of cardiovascular disease, transplantation and neurological disease. Prior to his move to Dublin, he was Professor of Proteomics at the Institute of Psychiatry, King's College London. Dr. Dunn is the current President of the British Society for Proteome Research and the Editor-in-Chief of the journal Proteomics. He is also a founder Council Member of the Human Proteome Organisation (HUPO) and a member of the Executive Committee of the HUPO Brain Proteome Project (BPP).
Inhaltsangabe
Editors Overview
PART 1: TECHNOLOGIES Pre-analytical issues in clinical proteomic studies Protein separation by 2DE Protein separation : liquid chromatography HPLC in protein discovery IEF analysis of peptides for biomarkers analysis Capillary electrophoresis separations for clinical proteomics Quantitative proteomics using nanoLC with high accuracy mass spectrometry Antibody microarrays for protein and glycan detection Biomarker Identification: The Role of Experimental Design, Statistics, and Data Sharing PART 2: CANCER Applications of stable isotope tagging based quantitive proteomics in cancer research 2-D liquid seperations, protein microarrays and mass spectrometry in comprehensive analysis of PTM and biomarker discovery Development and Use of Reversed-Phase Protein Microarrays for Clinical Applications CDK1 and cancer: usefulness of proteomic approaches in assesment of the molecular mechanisms and efficacy of novel therapeutics PART 3: CARDIOVASCULAR DISEASE Diagnostic markers for monitoring heart transplant rejection The study of microheterogeneity in human plasma proteins: applications to acute myocardial infarction Discovery of biomarkers for cardiovascular diseases Development of biomarker Developfment Pipeline: Search for Myocardial Ischemia Biomarkers Albuminome as a tool for biomarker discovery PART 4: VASCULAR DISEASES Application of Metabolomics to Cardiovascular Biomarker and Pathway Discovery Urinary biomarkers in diabetic nephropathy and other glomerular diseases Pulmonary proteomics Proteomics providing insights into major psychiatric disorders PART 6: BIOMARKERS Redox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer´s Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing Disorder Toxicoproteomics: correlating tissue and serum proteins in liver injuries Biomarkers for renal disease and uraemic toxins HIV and other viral screens PART 6: AUTOANTIBODIES AND SIGNATURE BIOMARKERS Application of Fungal Cyclic Peptides and Metabolites Microarray approaches to autoantibody profiling Identification of tumor antigen-directed autoantibodies PART 7: FUTURE Antibody and Reverse Capture Protein Microarrays Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases The Future: Translation from Discovery to the Clinic - Roles of HUPO and industry in biomarker discovery
PART 1: TECHNOLOGIES Pre-analytical issues in clinical proteomic studies Protein separation by 2DE Protein separation : liquid chromatography HPLC in protein discovery IEF analysis of peptides for biomarkers analysis Capillary electrophoresis separations for clinical proteomics Quantitative proteomics using nanoLC with high accuracy mass spectrometry Antibody microarrays for protein and glycan detection Biomarker Identification: The Role of Experimental Design, Statistics, and Data Sharing PART 2: CANCER Applications of stable isotope tagging based quantitive proteomics in cancer research 2-D liquid seperations, protein microarrays and mass spectrometry in comprehensive analysis of PTM and biomarker discovery Development and Use of Reversed-Phase Protein Microarrays for Clinical Applications CDK1 and cancer: usefulness of proteomic approaches in assesment of the molecular mechanisms and efficacy of novel therapeutics PART 3: CARDIOVASCULAR DISEASE Diagnostic markers for monitoring heart transplant rejection The study of microheterogeneity in human plasma proteins: applications to acute myocardial infarction Discovery of biomarkers for cardiovascular diseases Development of biomarker Developfment Pipeline: Search for Myocardial Ischemia Biomarkers Albuminome as a tool for biomarker discovery PART 4: VASCULAR DISEASES Application of Metabolomics to Cardiovascular Biomarker and Pathway Discovery Urinary biomarkers in diabetic nephropathy and other glomerular diseases Pulmonary proteomics Proteomics providing insights into major psychiatric disorders PART 6: BIOMARKERS Redox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer´s Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing Disorder Toxicoproteomics: correlating tissue and serum proteins in liver injuries Biomarkers for renal disease and uraemic toxins HIV and other viral screens PART 6: AUTOANTIBODIES AND SIGNATURE BIOMARKERS Application of Fungal Cyclic Peptides and Metabolites Microarray approaches to autoantibody profiling Identification of tumor antigen-directed autoantibodies PART 7: FUTURE Antibody and Reverse Capture Protein Microarrays Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases The Future: Translation from Discovery to the Clinic - Roles of HUPO and industry in biomarker discovery
Rezensionen
"Das Buch zeigt in einer sehr eindrucksvollen Gesamtschau, dass die Proteomik ein interessanter Ansatz ist, um die Diagnostik und Therapie zu verbessern.? Pharmazie in unserer Zeit Februar 2008
"Eine Zusammenstellung des aktuellen Wissenstands gibt das kürzlich erschienene Buch" Pharmazie in unserer Zeit, Februar 2008
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
